ライフサイエンスコーパス: postvaccination

1 or various exposure windows (i.e., intervals postvaccination).

2 cination and one due to malnutrition 70 days postvaccination.

3 as well as whole-group comparisons pre- and postvaccination.

4 period and for each year from 7 to 11 years postvaccination.

5 ccine recipients followed for up to 11 years postvaccination.

6 ease; 95% CI, 33.7-43.3; P < .0001) pre- and postvaccination.

7 gainst ASFV-G is highly effective by 28 days postvaccination.

8 P(+) cells in the muscle at days 3, 5, and 7 postvaccination.

9 s that enter the memory compartment 3 months postvaccination.

10 ated zoster vaccine efficacy through 4 years postvaccination.

11 ostvaccination and after as many as 140 days postvaccination.

12 demonstrate more robust changes pre- versus postvaccination.

13 serotypes 6B and 23F were evaluated 1 month postvaccination.

14 l 3 outcome measures from 7 through 11 years postvaccination.

15 o vaccination and at 1, 6, 12, and 18 months postvaccination.

16 ex immunoassay prevaccination and 30/60 days postvaccination.

17 ely to be an issue in the general population postvaccination.

18 ver 6 years and for 225 individuals pre- and postvaccination.

19 10 days) and long-term (6 months) protection postvaccination.

20 cted in the serological memory response 9 mo postvaccination.

21 nodes, when the animals were challenged 2 y postvaccination.

22 placebo and at 6 weeks, 1 year, and 2 years postvaccination.

23 rent increase in previously undetected types postvaccination.

24 n and for serious AEs (SAEs) through day 182 postvaccination.

25 esponses were maintained for up to 30 months postvaccination.

26 antigens) and remained elevated at 12 months postvaccination.

27 ostvaccination, and remained at 80% 80 weeks postvaccination.

28 ar, 3 years, and, when available, 6-10 years postvaccination.

29 an experiment with a challenge given 52 days postvaccination.

30 zing antibody titers were measured to 1 year postvaccination.

31 ies (titer, approximately 1:6,400) by day 26 postvaccination.

32 Antiviral antibodies were not observed postvaccination.

33 d CD4(+) T-cell proliferation also increased postvaccination.

34 allenge infection after 12, 16, and 20 weeks postvaccination.

35 ferior to 3D in adult women up to 120 months postvaccination.

36 (HAI) antibodies prevaccination and 1 month postvaccination.

37 nated with PA pDNA were challenged >7 months postvaccination.

38 s, VZV-specific CMI was increased at 6 weeks postvaccination.

39 ayed a major role in gene expression changes postvaccination.

40 rates were 92%/72%, and 73% were serotested postvaccination.

41 ecombinant vaccinia viruses (rVVs) at 5 days postvaccination.

42 ees are likely to be seropositive >=10 years postvaccination.

43 ody concentrations at baseline and 4-8 weeks postvaccination.

44 rived from axenic culture 7, 14, and 28 days postvaccination.

45 o significant difference was seen at 28 days postvaccination.

46 iae meningitis prevaccination and 20% (5/20) postvaccination.

47 whether mice were challenged at 7 or 28 days postvaccination.

48 ells to enhance the overall NK cell response postvaccination.

49 plus IL-15 (CD25 and IFN-gamma) was enhanced postvaccination.

50 indicating de novo expression of viral genes postvaccination.

51 isk factors for the development of arthritis postvaccination.

52 re elicited and maintained through 12 months postvaccination.

53 us AEs (SAEs) were recorded through 6 months postvaccination.

54 erse events (AEs) were recorded days 1 to 42 postvaccination.

55 equent high-dose DENV2 challenge at 19 weeks postvaccination.

56 sociated with H1N1-specific B cell responses postvaccination.

57 SFV Georgia 2007 isolate as early as 2 weeks postvaccination.

58 as well as lethal VEEV challenge at 8 months postvaccination.

59 gy was measured at baseline, 2 and 12 months postvaccination.

60 were challenged with RacL11 at various times postvaccination.

61 lent challenge with Brescia virus at 21 days postvaccination.

62 ion test (PRNT50) established that by day 62 postvaccination, 100% of animals seroconverted to DENV-1

63 ed the vaccines (prevaccination 2007-2009 vs postvaccination 2013-2016) in Sweden, where the 21 count

64 Antibody responses pre-/postvaccination (28 days, 6 months; in a subset [n = 566

65 Pre- and postvaccination Ab titers did not distinguish between su

66 .4%) vs 107 of 472 (22.7%) were seropositive postvaccination (absolute difference, 4.7% [95% CI, -1.4

67 memory CD8(+) T cells depended on the early postvaccination action of the inflammatory chemokines CC

68 the strongest differential signals on day 1 postvaccination, activating multiple innate immune pathw

69 ive immune responses, both postinfection and postvaccination, although no vaccine-development program

70 tion; 95% confidence interval [CI], 32%-63%) postvaccination among <5-year-olds.

71 eometric mean concentrations (GMCs) pre- and postvaccination among all age groups targeted for vaccin

72 ethal influenza infection after only 14 days postvaccination and after as many as 140 days postvaccin

73 between the two mouse strains at 24 and 72 h postvaccination and also performed unbiased total gene e

74 10(5) or 10(6) PFU Congo Basin MPXV 30 days postvaccination and evaluating morbidity and mortality.

75 spreading, and repertoire changes that arise postvaccination and following Ag-specific immunotherapie

76 ll adverse events (AEs) from day 1 to day 42 postvaccination and for serious AEs (SAEs) through day 1

77 ated mice by flow cytometry at 7 and 14 days postvaccination and found significantly more granulocyte

78 fornia/7/2009 virus were detected up to 4 wk postvaccination and higher in human CMV (HCMV)-seronegat

79 m pathogenic RacL11 challenge at 1 to 7 days postvaccination and increased the expression of IFN-gamm

80 Syncope is increasingly recognized postvaccination and may be associated with severe injury

81 ,S/AS01B are sustained for at least 6 months postvaccination and may translate to improved and more d

82 To identify mechanisms that act early postvaccination and might predict vaccine outcome, we im

83 1) achieved a protective response at 1 month postvaccination and none had a protective response at 12

84 za vaccine died, one due to anasarca 12 days postvaccination and one due to malnutrition 70 days post

85 aptive humoral and cellular immune responses postvaccination and postchallenge.

86 eutic targets to enhance antiviral responses postvaccination and postinfection.

87 tuberculosis, we examined cytokine responses postvaccination and recruitment of activated T cells and

88 Mucosal NKp44(+) ILCs increased postvaccination and returned to prelevels postinfection.

89 ll lack neutralizing antibodies at ~10 years postvaccination, and a booster vaccination should be con

90 chieved was tested at 6 months and at 1 year postvaccination, and mice challenged at these times rema

91 Seroprotection increased to 89% 8 weeks postvaccination, and remained at 80% 80 weeks postvaccin

92 28 days postvaccination, whereas at 21 days postvaccination, animals survived the lethal challenge b

93 wing subcutaneous RhCMV challenge at 8 weeks postvaccination, animals vaccinated with MVA-RhUL128C sh

94 who completed the vaccination series and had postvaccination anti-HBs titers available were identifie

95 All patients demonstrated an increase in postvaccination antibody and T cell responses against va

96 We also identified a gender difference in postvaccination antibody avidity (female < male subjects

97 Response to vaccination was defined as a postvaccination antibody concentration >=1.3 mug/mL for

98 concentrations resulted in 20% to 28% lower postvaccination antibody concentration (geometric mean r

99 ernal antibody was associated with 11% lower postvaccination antibody for pertussis toxoid (GMR, 0.89

100 ual variation and build predictive models of postvaccination antibody responses.

101 and 52 younger siblings who did not undergo postvaccination antibody tests (group 2) were studied.

102 were more compliant than male patients with postvaccination antibody titer measurements.

103 Average postvaccination antibody titers were similar across succ

104 Postvaccination antirotavirus IgA is a valuable correlat

105 m lethal VEEV and EEEV challenges at 1 month postvaccination as well as lethal VEEV challenge at 8 mo

106 s that expand in response to the YFV 2 weeks postvaccination (as defined by their unique T cell recep

107 Typhi: mean postvaccination bactericidal antibody titers were higher

108 >/=4-fold rise in antibody titer) at 1 month postvaccination based on serum hemagglutination inhibiti

109 nfected vaccinees, there was no correlation (postvaccination) between H1/stalk and HAI antibody respo

110 escribed, with a review of the literature on postvaccination BP.

111 Postvaccination cell-mediated immune (CMI) responses hav

112 ose seen using the glcV mutant in the 22-day postvaccination challenge.

113 The postvaccination changes (n-fold) in the percentages of i

114 rriage was a useful surrogate for monitoring postvaccination changes in the incidence of pneumococcal

115 ts a pattern of reduced and lagged epidemics postvaccination, closely matching the observed dynamics.

116 layed-type hypersensitivity reactions to E75 postvaccination compared with controls (33 v 7 mm; P < .

117 tween vaccinated and control villages in the postvaccination comparisons for either VT or NVT.

118 Postvaccination concentrations of neutralizing antibodie

119 quency of sepsis symptoms suggests that this postvaccination cytokine pattern may provide some non-M.

120 Postvaccination cytokine responses to CT-B were characte

121 Early postvaccination cytokine secretion and T lymphocyte and

122 ty was assessed on the basis of the ratio of postvaccination (day 22) geometric mean titers (GMTs) be

123 Pre- and postvaccination (day 26-30) serum specimens from 80 VV v

124 A postvaccination decrease in hospitalized community-acqui

125 Previously, we reported postvaccination delayed-type hypersensitivity (DTH) resp

126 titers of neutralizing antibodies at 7 days postvaccination (dpv), reaching a plateau at 29 dpv.

127 By 42 days postvaccination (DPV), the majority of pigs had seroconv

128 ination DTH was the single best predictor of postvaccination DTH.

129 s assessed by a change between pre-study and postvaccination enzyme-linked immunospot frequency of pu

130 In the postvaccination era, anti-HBc seropositivity is a useful

131 and IgG concentrations that persist 2 years postvaccination for all 13 serotypes, regardless of age

132 baseline (T0) and at 7 d (T1) and 28 d (T2) postvaccination for evaluation of immune responses.

133 confidence interval, 2.9%-9.5%) reduction in postvaccination functional antibody titers per year.

134 cant differences for any influenza strain in postvaccination geometric mean HI or MN titers.

135 tination inhibition seroconversion rates and postvaccination geometric mean titer ratios for each ant

136 TIV induced significantly higher postvaccination geometric mean titers against influenza

137 Prevaccination and postvaccination geometric mean titers were both signific

138 Two months postvaccination, GMCs to TT, PT, and PCV serotypes incre

139 ere was a strong inverse correlation between postvaccination GMT and risk of subsequent herpes zoster

140 to that of TIV on the basis of the ratio of postvaccination GMTs between the 2 vaccines.

141 Pre-and postvaccination granzyme B levels were significantly low

142 cases were less likely than noncases to have postvaccination HAI titers >/=32 or 64.

143 In the first season (2004-2005), postvaccination HAI titers >1:32 were noted for 31.6%, 4

144 In the second season (2005-2006), postvaccination HAI titers >1:32 were seen in 45.5%, 59.

145 d to administration of IIV-SD in both years, postvaccination HAI titers were significantly higher for

146 dies and was readily detectable despite high postvaccination HAI titers.

147 reciated and the mechanisms of NK activation postvaccination have been elucidated.

148 bodies, we generated antigenic maps based on postvaccination hemagglutination inhibition titers again

149 cancer screening, epidemiologic studies, and postvaccination HPV disease surveillance.

150 s over time do not suggest the potential for postvaccination HPV type replacement.

151 idal antibodies in normal, convalescent, and postvaccination human sera is important in understanding

152 elucidate the antibody epitope repertoire in postvaccination human sera.

153 Eleven of 18 postvaccination HZ specimens contained >1 strain, and 7

154 Postvaccination IgA GMCs were 22.1 U/mL, 26.5 U/mL, and

155 Postvaccination IgG anti-HAV were determined at 1, 6, an

156 .35ug/mL for vaccine serotypes, and 6 months postvaccination IgG concentrations >=0.35 ug/mL were mai

157 had significant increases in pre- to 1-month postvaccination IgG levels, but negligible to IgM, and s

158 were recruited to long-term memory 3 months postvaccination, (iii) the most highly expanded effector

159 NK cells contribute to postvaccination immune responses after activation by IL-

160 We then modeled partially effective postvaccination immune status 4 ways: use of PBMCs from

161 In concurrence with these findings, postvaccination immunoglobulin M concentrations were not

162 B may have the potential for causing harmful postvaccination immunologic (Koch-type) reactions.

163 of sustained cross-protection up to 8 years postvaccination in a high-risk population in the Netherl

164 LISA) geometric mean titers (GMTs) increased postvaccination in all rVSVDeltaG-ZEBOV-GP groups by 28

165 bstantial SBA decay was observed at 6 months postvaccination in both vaccine groups, although more ma

166 d a common transcriptional signature 28 days postvaccination in both young and older adults.

167 Postvaccination incidence of 4vHPV vaccine and nonvaccin

168 Postvaccination increases in gamma interferon production

169 in the three study groups combined; however, postvaccination increases in IFN-gamma were significant

170 In addition, postvaccination increases in serum bactericidal activity

171 Humoral responses postvaccination indicate that the vaccine candidate was

172 AIDS vaccines may be critical in determining postvaccination infection outcomes.

173 association between the smallpox vaccine and postvaccination ischemic events, we investigated alterat

174 in capsule-specific immunoglobulin G, with a postvaccination level >or=1000 ng/mL for at least 2 of t

175 Pre- and postvaccination levels of anti-HIV activity were signifi

176 Postvaccination levels of IL-2 were significantly greate

177 o become seronegative between 3 and 12 years postvaccination (logistic regression, odds ratio [OR] =

178 Postvaccination lot quality assurance sampling and chron

179 an growth ratio [GR], 9.6; range, 1.3 to 24; postvaccination median GR, 3.9; range, 0.6 to 12.2 [P <

180 throughout 2011 in the 3 districts, overall postvaccination meningococcal carriage prevalence was 6.

181 When challenged at 2 wk postvaccination, mice receiving AgDNA or ALM/rIL-12 were

182 ate large-scale serological surveillance and postvaccination monitoring.

183 vious clinical study, more than one-third of postvaccination nasal wash isolates exhibited partial lo

184 Two years postvaccination, nearly all of the 800 participants (99.

185 ine was judged superior on the basis of mean postvaccination neutralizing antibody titers (12.5 vs. 1

186 Postvaccination neutralizing antibody titers to 3c2.A an

187 Postvaccination neutralizing antibody titers to H1N1 wer

188 Although IL-2-dependent postvaccination NK cell activation has been reported pre

189 Postvaccination NKp44(+) and NKp44(+)IL-17(+) ILC freque

190 ation (P = 0.863), and BLyS levels increased postvaccination only in the subset of patients with BLyS

191 There was good agreement between postvaccination opsonic and IgG antibody levels.

192 ody levels to PPV23 serotypes also increased postvaccination (P < .001).

193 Male macaques postvaccination (p = 0.018) and postinfection (p = 0.004

194 ination, and 96 during the equivalent period postvaccination (p=0.009).

195 mean titer [GMT], 151 vs. 1010 for pre- vs. postvaccination; P<.001), whereas anti-L1 antibody respo

196 e (prevaccination period [PreVP]) and after (postvaccination period [PostVP]) introduction of UMV.

197 7) for all confirmed cases during the 8-week postvaccination period and was 2.75 (95% CI, 1.63-4.62)

198 d, relative risk estimates during the 4-week postvaccination period were 3.02 (95% CI, 1.64-5.56) for

199 s changes in depressive symptoms, during the postvaccination period.

200 s 2.75 (95% CI, 1.63-4.62) during the 4-week postvaccination period.

201 iffer appreciably between risk groups in the postvaccination period.

202 , deaths, and cost-effectiveness over a 30-y postvaccination period.

203 8 complex) was compared between the pre- and postvaccination periods.

204 that monomeric Env-specific IgA, as part of postvaccination polyclonal antibody response, may modula

205 ctin-like receptor B1 (KLRB1; CD161) 28 days postvaccination positively and negatively predicted vacc

206 We determined if the ability of postvaccination, prechallenge sera to enhance SIVmac251

207 Hib-specific sequences, indicating that the postvaccination public BCR repertoire may be related to

208 cimens obtained from vaccine recipients with postvaccination rash or herpes zoster (HZ), focusing on

209 All 21 postvaccination rash specimens contained mixtures of vac

210 Tumor cells from postvaccination resections showed significantly lower TR

211 of 59 (24%) HCWs 10-15, 16-20, and >20 years postvaccination, respectively, (P = ns).

212 %), for the first 3, and subsequent 4+ years postvaccination, respectively.

213 Pre- and postvaccination responses of HI and neutralizing antibod

214 crease with age, which may lead to different postvaccination responses to emerging influenza variants

215 suggest an age-specific difference in human postvaccination responses.

216 Analysis of the adaptive immune response postvaccination revealed robust specific T- and B-cell r

217 Thirty days postvaccination, RSV-A neutralizing antibody geometric m

218 in prevaccination serum samples (Vi) and in postvaccination samples (Vi and rabies).

219 Prevaccination and 6-week postvaccination samples from the immunogenicity substudy

220 At 1 year and 4 years (only for study A) postvaccination, SBA titers were relatively sustained in

221 icantly enhanced when BCG was opsonized with postvaccination sera (P < .01), and these enhancements c

222 Postvaccination sera also prevented NS1-induced degradat

223 d from a densely infiltrated metastasis with postvaccination sera from a long-term responding patient

224 Pre- and postvaccination sera from kidney transplant recipients (

225 pitopes in HA1/HA2 and NA were recognized by postvaccination sera from the two high-dose groups, incl

226 We determined that postvaccination sera increased the uptake of wild-type S

227 Analysis of 793 prevaccination and 800 postvaccination sera indicated that while GMCs were low

228 Using pre- and postvaccination sera of people immunized with the 23-val

229 Effects of prevaccination and postvaccination sera on BCG phagocytosis and intracellul

230 is a fourfold rise in titer between pre- and postvaccination sera or if there is a characteristic boo

231 s reduced as much as 50% when opsonized with postvaccination sera relative to day 0 or placebo serum

232 Typhi when the bacteria were opsonized with postvaccination sera than when the bacteria were opsoniz

233 The growth-inhibiting effects of postvaccination sera were reversed by preabsorption of I

234 Antigenic maps derived from human postvaccination sera with H1 influenza preexposure also

235 contrast, antigenic maps derived from human postvaccination sera with only type B influenza preexpos

236 oss-reactive bactericidal activity, and some postvaccination sera, was analyzed to determine the spec

237 ased phagolysosomal fusion was observed with postvaccination sera.

238 Frequency of postvaccination seroconversion did not significantly dif

239 infant and contact identification; pre- and postvaccination serologic testing in contacts and infant

240 etection of S. pneumoniae, which may improve postvaccination serotype surveillance.

241 s (or >83% of serotypes with data) achieving postvaccination serotype-specific immunoglobulin G >=0.3

242 activated hapten-specific B cells determines postvaccination serum Ab levels and vaccine efficacy.

243 Postvaccination serum samples from elderly subjects demo

244 e median age at vaccination was 12.5 months; postvaccination serum samples were obtained on average 4

245 ls was shown to be significantly enhanced in postvaccination serum samples.

246 itulated using immunoglobulins purified from postvaccination serum, demonstrating that antibodies wer

247 rcinogenic HPV types; continued surveillance postvaccination should improve our understanding of the

248 PBMC collected 30 d postvaccination showed heightened cytokine production in

249 At 10 weeks postvaccination, splenic gamma interferon (IFN-gamma) mR

250 The anti-Hib avidity index postvaccination strongly correlated with the relative fr

251 8(+) T cells were still detected at 5 months postvaccination, suggesting that MVA-H5M provides long-l

252 s obtained during 1550 diarrheal episodes in postvaccination surveillance were rotavirus-positive by

253 vaccination serological survey in 2010 and a postvaccination survey in 2012.

254 verse events through month 13; and solicited postvaccination symptoms through day 7.

255 Solicited postvaccination symptoms were generally mild with more l

256 Magnitudes of pre- and postvaccination T-cell responses were lower in HIV-infec

257 PCR was positive for longer times postvaccination than was SVA.

258 mong the vaccinated animals, but by 7 months postvaccination there was a substantial antigen-specific

259 in part by faster declines with higher peak postvaccination titer.

260 tibody is the major correlate of protection, postvaccination titers alone should not be used as a sur

261 Mean postvaccination titers for individuals who received HD v

262 Postvaccination titers in Flucelvax recipients were low

263 ly all recipients of inactivated vaccine had postvaccination titers of at least 64, and the small num

264 Postvaccination titers to 3c2.A and 3c2.A2 were similar

265 ain; for those who received SD vaccine, mean postvaccination titers were as 67 for H1N1, 333 for H3N2

266 unoglobulin G was assayed before and 4 weeks postvaccination to calculate the antibody response ratio

267 sfer of naive 1807 cells at serial intervals postvaccination uncovered the prolonged duration of fung

268 rrence of HZ for >/=1 year (mean, 1.3 years) postvaccination until accrual of >/=96 confirmed HZ case

269 inin antibody inhibition titers from 1 month postvaccination until end-of-study participation.

270 various time points, until 2 years (day 720) postvaccination, upon which a subset from each group was

271 Antibody levels >24 months postvaccination using extended dosing schedules is unkno

272 B influenza virus strains collected pre- and postvaccination using hemagglutination inhibition (HI) a

273 allenge with the virulent strains at 21 days postvaccination, vaccinated animals showed neither any c

274 cutoff and twofold increase between pre and postvaccination values for <70% of serotypes).

275 sion of Oka VZV from vaccine recipients with postvaccination vesicular rashes was identified in 3 sus

276 Both baseline and postvaccination VZV-specific CMI were lower in the older

277 enerally correlated with higher baseline and postvaccination VZV-specific CMI.

278 D69(+)CD57(+)PD1(+) T cells from baseline to postvaccination was associated with concurrent decreased

279 Blood taken prevaccination and 1 week postvaccination was tested for immunoglobulin G antibodi

280 Three days postvaccination, we found higher T cell activation marke

281 s based on studies focusing on the immediate postvaccination weeks.

282 measured on both cell types at 2 to 6 weeks postvaccination were comparable to levels observed in na

283 40 plus a >/=4-fold increase over T0 at 3 wk postvaccination were designated as responders.

284 oncentrations before and 8, 32, and 80 weeks postvaccination were determined by plaque reduction neut

285 antigen and challenged intranasally 4 weeks postvaccination were protected against sublethal and let

286 uses from nasal swabs taken 1, 3, and 6 days postvaccination were quantified by reverse-transcription

287 l assays indicated that antibodies generated postvaccination were recognized by complement factors an

288 Tonsils and peripheral blood (pre- and postvaccination) were collected to study T-cell response

289 nst ASFV-G is highly effective after 28 days postvaccination, whereas at 21 days postvaccination, ani

290 e efficacy for HZ BOI persisted into year 10 postvaccination, whereas statistically significant vacci

291 nificantly greater than zero through year 10 postvaccination, whereas vaccine efficacy for incidence

292 ansion in the draining lymph nodes at 6 days postvaccination, which persisted for 2 wk.

293 inst virulent C. burnetii as early as 7 days postvaccination, which suggests that ACCM-2-derived PIV

294 ild-type counterparts when challenged 7 days postvaccination, while no significant difference was see

295 After the cART interruption at week 12 postvaccination, while total HIV-1 DNA increased signifi

296 om DENV-naive or preimmune subjects pre- and postvaccination with TAK-003 and evaluated the functiona

297 utant and subsequent oral challenge (22 days postvaccination) with the parent revealed a ca. 10,000-f

298 n from lethal challenge was observed by 24 h postvaccination, with 100% protection induced in as litt

299 ects reporting SAEs occurring within 42 days postvaccination (ZV, 0.6%; placebo, 0.5%) and 182 days p

300 ation (ZV, 0.6%; placebo, 0.5%) and 182 days postvaccination (ZV, 2.1%; placebo, 1.9%) was similar be